Professor Robert Storey

Meet interventional cardiologist and guidelines author Professor Rob Storey and learn his views on the best regimen of antithrombotic therapy for AF patients with ACS and/or PCI in these video interviews.

  • Professor Rob Storey

    Professor Storey introduces himself and details his research interests and guideline involvement.

    View More

  • What unmet need still exists and how is the landscape evolving for patients with atrial fibrillation and ACS undergoing PCI?

    Learn about the challenge of treating patients with atrial fibrillation who have presentation with acute coronary syndrome and or need percutaneous coronary intervention.

    View More

  • How do you think this unmet need could be overcome?

    Professor Storey gives his view on how to individualise therapy most effectively.

    View More

  • How do you feel the landscape is evolving for patients with atrial fibrillation and ACS and/or PCI?

    Find out about the more recent studies looking at the critical endpoints of stroke and stent thrombosis prevention in this patient population.

    View More

  • What is the best regimen of antithrombotic therapy for AF patients with ACS and/or PCI?

    Find out if a direct oral anticoagulant (DOAC) is better than a vitamin K antagonist in trying to balance efficacy and safety in these patients.

    View More

  • Do you think the AUGUSTUS results will change cardiologist prescribing habits?

    Find out when it is safe to drop aspirin.

    View More

  • In your opinion why was the AUGUSTUS trial such a game changer?

    Learn about the importance of the 2x2 factorial design of the AUGUSTUS trial.

    View More

  • Where do we go now after the AUGUSTUS trial?

    Find out why we still need to identify patients that require more intensive therapy.

    View More

  • What’s the future of anticoagulation management in atrial fibrillation?

    Is triple therapy on the way out?

    View More

  • Why do you feel cardiologists are distrustful of real-world evidence?

    Find out Professor Storey’s concerns on the robustness of real-world evidence.

    View More

  • What can be done to challenge the perception that real world data is of less value than RCTs in decision making?

    Surely clinical trials are also carried out in the real world?

    View More

  • What are your views on the robustness of the current guidelines?

    Find out how the ESC guidelines on chronic coronary syndromes have taken onboard the evidence from AUGUSTUS and more recent studies.

    View More


    Back to Expert Opinion
    Login/ Register Maximise Minimise